top of page

GlobalData on the difficulties and opportunities of Brexit for pharma

While the exit of the UK from the EU undoubtedly creates significant issues for the UK pharmaceutical industry in ensuring highly regulated European markets remain open to business, opportunities remain for the sector to thrive, according to research and consulting firm GlobalData.

Click on this link for more information.



Today's News
Follow us
  • LinkedIn Social Icon
  • Vimeo Social Icon
Newsletter on Pharma Legislation
the newsletter of
bottom of page